Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act.

Saloner, Brendan; Andraka-Christou, Barbara; Stein, Bradley D; Gordon, Adam J

Saloner, Brendan; Andraka-Christou, Barbara; Stein, Bradley D; Gordon, Adam J.

Affiliation

Saloner B; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Andraka-Christou B; School of Global Health Management and Informatics, University of Central Florida, Orlando, FL, USA.
Stein BD; RAND Corporation, Pittsburgh, PA, USA.
Gordon AJ; Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

Subst Abus ; 44(3): 108-111, 2023 07.

Article in En | MEDLINE | ID: mdl-37675897

Subject(s)

Buprenorphine; Opioid-Related Disorders; Humans; Buprenorphine/therapeutic use; Opiate Substitution Treatment; Opioid-Related Disorders/drug therapy; Surveys and Questionnaires; Credentialing

Key words

X waiver; buprenorphine; medications for opioid use disorder

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Buprenorphine / Opioid-Related Disorders Type of study: Guideline Limits: Humans Language: En Journal: Subst Abus Journal subject: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Year: 2023 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google